DUBLIN--(BUSINESS WIRE)--The "Ewing Sarcoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 5, 1, 23 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.
Key Topics Covered
- Introduction
- Ewing Sarcoma - Overview
- Ewing Sarcoma - Therapeutics Development
- Ewing Sarcoma - Therapeutics Assessment
- Ewing Sarcoma - Companies Involved in Therapeutics Development
- Ewing Sarcoma - Drug Profiles
- Ewing Sarcoma - Dormant Projects
- Ewing Sarcoma - Discontinued Products
- Ewing Sarcoma - Product Development Milestones
- Appendix
Companies Mentioned
- Amgen Inc
- AntiCancer Inc
- Astellas Pharma Inc
- Bristol-Myers Squibb Co
- Cebiotex SL
- Celgene Corp
- Celldex Therapeutics Inc
- Cellectar Biosciences Inc
- Eisai Co Ltd
- EntreChem SL
- Exelixis Inc
- Gradalis Inc
- Incyte Corp
- Ipsen
For more information about this report visit https://www.researchandmarkets.com/research/8ndvpn/ewing_sarcoma?w=4
